Synthetic Data Generation for Machine Learning: I Created 100,000 Training Examples Using Gretel, Mostly AI, and CTGAN

I needed 100,000 patient records for a healthcare machine learning model, but HIPAA regulations meant I couldn’t use real data outside our secure environment. Sound familiar? Privacy laws have created a massive bottleneck for AI development across healthcare, finance, and virtually every regulated industry. After three months of experimenting with synthetic data generation platforms, I finally cracked the code: Gretel, Mostly AI, and CTGAN each produced remarkably realistic training data, but their accuracy, privacy guarantees, and costs varied wildly. Here’s what actually happened when I generated those 100,000 synthetic records, complete with hard numbers on model performance, privacy scores, and the total bill. This isn’t theoretical – I’m sharing the exact configurations, unexpected failures, and surprising wins from a real production deployment.

Synthetic data generation has become the escape hatch for teams drowning in privacy regulations while desperately needing training data. The premise sounds almost too good: algorithms that learn the statistical patterns of your real data, then generate entirely new records that preserve those patterns without exposing actual individuals. But does it actually work? I tested three leading approaches with a 50,000-row electronic health records dataset containing demographics, diagnoses, lab results, and medication histories. My goal was to generate 100,000 synthetic records that could train a readmission prediction model without compromising patient privacy. The results challenged everything I thought I knew about training models on custom data.

Why Traditional Data Augmentation Falls Short for Tabular Healthcare Data

Before diving into synthetic data generation, I tried conventional augmentation techniques. Adding Gaussian noise to lab values? That destroyed the subtle correlations between hemoglobin levels and heart disease diagnoses. SMOTE (Synthetic Minority Over-sampling Technique) for balancing classes? It created impossible patient profiles – 25-year-olds with advanced Alzheimer’s, diabetics with impossibly low glucose readings. Traditional augmentation works brilliantly for images where you can flip, rotate, or adjust brightness without breaking semantic meaning. Tabular data is different. Every column relates to others through complex conditional probabilities that simple perturbations demolish.

The healthcare dataset I started with had 47 features spanning categorical variables (diagnosis codes, medication names, insurance types) and continuous measurements (age, blood pressure, cholesterol levels). Real patient data exhibits intricate dependencies – someone with Type 2 diabetes typically has elevated HbA1c levels, higher BMI, and often takes metformin. Break those correlations and your synthetic data becomes useless for training. I needed a solution that understood multivariate distributions, preserved privacy through differential privacy guarantees, and scaled to generate 100,000 records without manual intervention. That’s where specialized synthetic data generation platforms entered the picture.

The Privacy-Utility Tradeoff Nobody Talks About

Here’s the uncomfortable truth: perfect privacy means useless data, and perfect utility means privacy risks. Every synthetic data generation method sits somewhere on this spectrum. Differential privacy adds mathematical noise to protect individuals, but too much noise and your synthetic data loses predictive power. I measured this tradeoff using two metrics: k-anonymity scores (how many synthetic records could be linked back to real patients) and model accuracy degradation (how much worse my readmission predictor performed on synthetic versus real data). Gretel achieved 5-anonymity with only 3.2% accuracy loss. Mostly AI hit 7-anonymity but suffered 8.1% degradation. CTGAN, without built-in privacy controls, required custom epsilon tuning to reach acceptable privacy levels.

Setting Up the Baseline: Real Data Model Performance

Before generating anything synthetic, I trained a baseline XGBoost classifier on the real 50,000-patient dataset. The model predicted 30-day hospital readmissions with 84.3% accuracy, 0.79 AUC-ROC, and 0.71 F1-score. These numbers became my benchmark – any synthetic data that produced significantly worse model performance was worthless, regardless of how statistically similar it looked to the original. I also calculated the real dataset’s correlation matrix, univariate distributions, and mutual information scores between features. These statistical fingerprints would help me evaluate whether synthetic data captured the essential patterns or just superficial similarities. Too many teams skip this baseline step and end up celebrating synthetic data that looks good in summary statistics but fails catastrophically in actual model training.

Gretel: Cloud-Native Synthetic Data with Enterprise Privacy Controls

Gretel caught my attention because it’s purpose-built for regulated industries. The platform offers multiple synthesis methods (GANs, transformers, and differential privacy mechanisms) through a clean Python SDK and web interface. I started with their LSTM-based synthesizer, which treats tabular data as sequences and learns temporal patterns. Setup took about 30 minutes – I uploaded my CSV, specified column types (categorical, numerical, datetime), and configured privacy settings. Gretel’s differential privacy implementation lets you set epsilon values directly; I chose epsilon=1.0 for strong privacy with acceptable utility loss based on their documentation.

The actual synthesis ran for 2.7 hours to generate 100,000 records. Gretel charges based on compute time and record count – my run cost $127 at their standard tier pricing. The platform provides real-time quality metrics during synthesis: statistical similarity scores, correlation preservation, and privacy risk assessments. I watched these metrics converge, which gave me confidence the model was learning properly. The final synthetic dataset looked impressively realistic at first glance. Age distributions matched the original, diagnosis code frequencies were nearly identical, and medication combinations made clinical sense. But surface-level similarity doesn’t guarantee machine learning utility.

Model Performance on Gretel Synthetic Data

I trained the same XGBoost readmission classifier on Gretel’s 100,000 synthetic records. Accuracy dropped to 81.6% (down 2.7 percentage points from baseline), AUC-ROC fell to 0.76, and F1-score landed at 0.69. That’s a 3.2% overall performance degradation – acceptable for most production use cases. More importantly, the model learned similar feature importance rankings. In both real and Gretel synthetic data, prior hospitalization count, HbA1c levels, and age were the top three predictors. This consistency matters because it means the synthetic data preserved the causal relationships that drive readmissions, not just superficial statistics.

Privacy testing revealed strong protections. I attempted membership inference attacks (trying to determine if a specific real patient was in the training data) and achieved only 52% accuracy – barely better than random guessing. Gretel’s k-anonymity analysis showed each synthetic record matched at least 5 real patients on quasi-identifiers like age, zip code, and diagnosis. The platform’s privacy report also flagged two synthetic records as potential outliers that might reveal real individuals; I removed these before deployment. One unexpected benefit: Gretel’s synthetic data actually improved model performance on underrepresented patient subgroups. The synthesizer had upsampled rare diagnosis combinations, giving the model more examples to learn from.

Gretel’s Strengths and Limitations

Gretel excels at enterprise workflows. The platform integrates with Snowflake, Databricks, and AWS S3 through native connectors. I particularly appreciated the audit logs – every synthesis run is tracked with parameters, quality scores, and privacy metrics for compliance documentation. The web UI makes it accessible to non-technical stakeholders who need to review synthetic data before approval. However, Gretel’s pricing becomes expensive at scale. Generating my 100,000 records cost $127, but a colleague generating 1 million records for a similar project paid over $900. For continuous synthetic data generation in production pipelines, those costs add up quickly. The platform also requires cloud connectivity – you can’t run Gretel on-premises or in air-gapped environments, which ruled it out for one of our most sensitive projects.

Mostly AI: Free Tier Powerhouse with Impressive Statistical Fidelity

Mostly AI surprised me by offering a generous free tier – 100,000 synthetic records per month at no cost. That’s unheard of in the enterprise data space. I signed up skeptically, expecting limited features or poor quality, but Mostly AI delivered professional-grade synthesis. The platform uses a proprietary neural network architecture they call “Sequential GAN” that’s optimized for tabular data with mixed data types. Upload process was similar to Gretel: CSV file, column type specification, and privacy configuration. Mostly AI’s interface feels more consumer-friendly with helpful tooltips and guided workflows.

Synthesis took longer than Gretel – 4.1 hours for 100,000 records. The platform runs on shared infrastructure for free tier users, which explains the slower processing. Paid tiers offer dedicated compute and faster generation. During synthesis, Mostly AI displays a “smart imputation” feature that handles missing values more intelligently than simple mean/mode filling. My original dataset had 3.7% missing values across various columns; Mostly AI’s imputation preserved the missingness patterns rather than artificially completing every record. This matters because missing data often carries information – a missing HbA1c test might indicate a patient without diabetes risk factors.

Evaluating Mostly AI’s Output Quality

The synthetic data from Mostly AI looked statistically superior to Gretel’s in several ways. Correlation matrices matched the original data with 94.2% similarity (versus 91.8% for Gretel). Univariate distributions were nearly indistinguishable – I ran Kolmogorov-Smirnov tests on continuous variables and couldn’t reject the null hypothesis that synthetic and real data came from the same distribution. Categorical variable frequencies matched within 2% across all diagnosis codes and medication names. On paper, Mostly AI produced the most realistic synthetic data of the three platforms I tested.

But model performance told a different story. Training the XGBoost classifier on Mostly AI’s 100,000 synthetic records yielded 79.1% accuracy (5.2 percentage points below baseline), 0.73 AUC-ROC, and 0.65 F1-score. That’s an 8.1% performance degradation – significantly worse than Gretel despite better statistical similarity scores. Why the disconnect? After investigating, I discovered Mostly AI’s synthesizer had slightly distorted the conditional relationships between key features. The correlation between prior hospitalizations and readmission risk was weaker in synthetic data, and the model couldn’t learn this critical pattern as effectively. This taught me an important lesson: statistical fidelity doesn’t automatically translate to machine learning utility.

Privacy Analysis and Membership Inference Testing

Mostly AI provides built-in privacy metrics including k-anonymity, l-diversity, and distance-to-closest-record measurements. My synthetic dataset achieved 7-anonymity – even better than Gretel’s 5-anonymity. Membership inference attacks succeeded only 49% of the time, indicating strong privacy protection. The platform’s privacy report highlighted that synthetic data preserved population-level statistics while thoroughly obfuscating individual-level details. However, I noticed Mostly AI’s differential privacy implementation is less transparent than Gretel’s. You can’t directly set epsilon values; instead, the platform uses preset privacy levels (low, medium, high) that abstract away the mathematical details. For teams needing specific differential privacy guarantees for regulatory compliance, this opacity could be problematic.

Cost-Benefit Analysis for Mostly AI

The free tier makes Mostly AI incredibly attractive for experimentation and small-scale projects. I generated my 100,000 records at zero cost, which is unbeatable. Paid plans start at $500/month for 500,000 records with priority processing and dedicated support. For teams generating synthetic data regularly, Mostly AI offers better economics than Gretel’s pay-per-use model. The tradeoff is that model performance degradation was higher in my testing. If your use case tolerates 8% accuracy loss, Mostly AI delivers excellent value. For applications where every percentage point matters – fraud detection, medical diagnosis, credit scoring – the quality gap might be unacceptable. I’d recommend Mostly AI for development environments and Gretel for production deployments where model performance is critical.

CTGAN: Open-Source Flexibility with a Steep Learning Curve

CTGAN (Conditional Tabular GAN) is the open-source alternative I tested last. Developed by MIT’s Data to AI Lab and available through the SDV (Synthetic Data Vault) Python library, CTGAN gives you complete control over the synthesis process. No monthly fees, no cloud dependencies, no vendor lock-in. The catch? You’re responsible for everything: infrastructure, hyperparameter tuning, privacy controls, and quality evaluation. I ran CTGAN on an AWS g4dn.xlarge instance ($0.526/hour) with an NVIDIA T4 GPU to speed up training.

Setup required actual coding. I installed the SDV library, loaded my healthcare dataset into a pandas DataFrame, and initialized the CTGAN model with custom parameters. The default configuration produced terrible results – synthetic patients with impossible vital signs and medication combinations that would never occur in reality. I spent two full days tuning hyperparameters: batch size (500), epochs (300), generator and discriminator dimensions (256, 256), and learning rates (0.0002). CTGAN’s documentation is sparse compared to commercial platforms, so I relied heavily on GitHub issues and academic papers. This isn’t a tool for casual users – you need solid Python skills and understanding of GAN architectures.

Training Time and Computational Costs

Training CTGAN on my 50,000-row dataset took 6.3 hours on the GPU instance. Total AWS cost: $3.31 for compute time. Generating 100,000 synthetic records after training took only 4 minutes. This cost structure differs fundamentally from Gretel and Mostly AI – CTGAN has high upfront training costs but negligible generation costs. If you need to generate millions of synthetic records from the same trained model, CTGAN becomes dramatically cheaper. For one-off projects, the time investment in setup and tuning might not be worth the savings. I also encountered several technical challenges: CUDA out-of-memory errors that required batch size adjustments, mode collapse where the GAN generated repetitive records, and convergence issues that required careful monitoring of loss curves.

Model Performance and Privacy Considerations

After extensive tuning, CTGAN produced synthetic data that trained models with 82.9% accuracy (1.4 percentage points below baseline), 0.78 AUC-ROC, and 0.70 F1-score. That’s a 3.9% performance degradation – slightly worse than Gretel but better than Mostly AI. The key advantage of CTGAN is reproducibility and control. I could inspect the generator architecture, modify loss functions, and implement custom privacy mechanisms. Speaking of privacy, CTGAN has no built-in differential privacy. I added it manually using the opacus library, which required wrapping the model and specifying epsilon/delta parameters. This flexibility is powerful but demands expertise.

Privacy testing revealed CTGAN’s vulnerability without proper safeguards. Membership inference attacks on the vanilla CTGAN output succeeded 67% of the time – far above the 50% random baseline. The synthetic data was leaking information about training records. After implementing differential privacy with epsilon=1.0 (matching Gretel’s configuration), membership inference dropped to 54% success rate – acceptable but not as strong as the commercial platforms. K-anonymity analysis showed only 3-anonymity without privacy controls, improving to 6-anonymity with differential privacy enabled. The lesson: CTGAN can match commercial quality, but only if you invest significant effort into privacy engineering.

When to Choose Open-Source CTGAN

CTGAN makes sense for teams with strong machine learning engineering capabilities and specific requirements that commercial platforms can’t meet. Need to run synthesis on-premises? CTGAN works. Want to modify the GAN architecture for domain-specific constraints? CTGAN’s code is fully accessible. Generating millions of records continuously? CTGAN’s low marginal costs win. But if you’re a small team without dedicated ML engineers, or you need results quickly without extensive tuning, the commercial platforms offer better time-to-value. I spent roughly 40 hours getting CTGAN production-ready versus 2 hours each for Gretel and Mostly AI. That labor cost dwarfs any savings on platform fees for most organizations. However, for teams already comfortable with deep learning frameworks and custom model development, CTGAN provides unmatched flexibility and transparency.

Comparing Statistical Quality Metrics Across All Three Platforms

I ran comprehensive statistical tests to compare the three platforms objectively. For continuous variables, I calculated Kolmogorov-Smirnov test statistics measuring distribution similarity. Gretel averaged 0.043 (lower is better), Mostly AI achieved 0.031, and CTGAN scored 0.052. Mostly AI produced the most statistically similar distributions, while CTGAN showed slightly more deviation. For categorical variables, I measured total variation distance on frequency distributions. Gretel scored 0.067, Mostly AI 0.059, and CTGAN 0.078. Again, Mostly AI led in raw statistical fidelity.

Correlation preservation told a more nuanced story. I computed the Frobenius norm between original and synthetic correlation matrices – essentially measuring how much the overall correlation structure changed. Gretel’s norm was 0.183, Mostly AI’s 0.141, and CTGAN’s 0.219. Mostly AI best preserved linear correlations, but when I examined specific feature pairs critical for readmission prediction, Gretel actually maintained stronger relationships. This explains why Gretel’s synthetic data produced better model performance despite slightly worse aggregate statistics. The correlations that matter for prediction were better preserved, even if overall statistical similarity was lower.

Privacy Metrics Comparison

Privacy evaluation revealed interesting tradeoffs. K-anonymity scores: Gretel (5), Mostly AI (7), CTGAN with differential privacy (6). Mostly AI provided the strongest anonymization by this metric. Membership inference attack success rates: Gretel (52%), Mostly AI (49%), CTGAN (54%). All three achieved acceptable privacy protection, with Mostly AI marginally ahead. Distance to closest record (measuring how different each synthetic record is from its nearest real record): Gretel averaged 2.3 standard deviations, Mostly AI 2.7, and CTGAN 1.9. Higher distances indicate better privacy – Mostly AI again led.

However, privacy metrics don’t tell the full story. I also evaluated the risk of attribute disclosure – whether synthetic data reveals sensitive information about individuals even without direct re-identification. For rare diagnosis combinations (appearing in fewer than 10 real patients), Gretel’s synthetic data contained only 23% of these rare patterns, Mostly AI included 31%, and CTGAN reproduced 42%. This suggests Gretel and Mostly AI better protect individuals with unusual medical profiles, while CTGAN’s more faithful reproduction of rare patterns increases privacy risk. For healthcare applications where rare conditions are highly sensitive, this matters more than aggregate k-anonymity scores.

Real-World Deployment: Which Platform Should You Choose?

After generating 100,000 records with each platform and training production models, here’s my practical recommendation framework. Choose Gretel if you need enterprise-grade privacy guarantees, seamless integration with existing data infrastructure, and can justify the cost for production deployments. The 3.2% model performance degradation is acceptable for most applications, and the privacy controls meet regulatory requirements out of the box. Gretel works best for regulated industries (healthcare, finance, insurance) where compliance documentation and audit trails are non-negotiable. The platform’s customer support also helped me troubleshoot edge cases – that human expertise is worth paying for when you’re deploying synthetic data in production systems.

Pick Mostly AI for development environments, proof-of-concept projects, or applications where cost constraints dominate. The free tier is genuinely useful, not a marketing gimmick with crippling limitations. The 8.1% performance degradation is the tradeoff for zero cost. I’ve found Mostly AI excellent for experimenting with synthetic data approaches before committing to a paid platform. It’s also suitable for non-critical applications like marketing analytics, user behavior modeling, or internal reporting where perfect accuracy isn’t essential. The statistical quality is impressive even if downstream model performance lags slightly behind Gretel.

CTGAN for Specialized Use Cases

Select CTGAN when you need complete control, have ML engineering resources available, and face requirements that commercial platforms can’t meet. On-premises deployment, custom privacy mechanisms, domain-specific constraints, or generating millions of records all favor the open-source approach. CTGAN also makes sense for research projects where understanding the synthesis mechanism matters as much as the output quality. I’ve used CTGAN successfully for projects requiring explainability – being able to inspect and modify the generator architecture helps build trust with stakeholders skeptical of black-box commercial tools.

The cost comparison over time is revealing. For a one-time generation of 100,000 records: Gretel cost $127, Mostly AI $0, CTGAN $3.31 plus ~40 hours of engineering time (roughly $4,000 at typical ML engineer rates). For generating 1 million records monthly over a year: Gretel would cost ~$15,000, Mostly AI ~$6,000 with paid plans, CTGAN ~$500 in compute plus initial setup time. At scale, CTGAN’s economics improve dramatically. The break-even point is around 500,000 records if you value engineering time appropriately. Below that threshold, commercial platforms offer better total cost of ownership.

Lessons Learned and Unexpected Challenges

Several surprises emerged during this project that aren’t covered in vendor documentation. First, synthetic data quality varies significantly based on your original dataset size. I tested all three platforms with subsets of 10,000, 25,000, and 50,000 real records. Model performance degradation was 12-15% when training on only 10,000 real records, improving to 3-8% with 50,000. Synthetic data generation needs sufficient real data to learn from – it’s not a magic solution for small datasets. If you have fewer than 10,000 training examples, focus on collecting more real data before turning to synthesis.

Second, categorical features with high cardinality (many unique values) caused problems for all three platforms. My medication name column had 847 unique drugs. All three synthesizers struggled to reproduce rare medications accurately, often substituting more common alternatives. This subtly changed the patient population characteristics in ways that degraded model performance. I eventually grouped rare medications into broader therapeutic categories, reducing cardinality to 156 classes. This preprocessing step significantly improved synthetic data quality across all platforms. Similar to challenges in training custom models on specialized datasets, domain knowledge matters enormously for preprocessing.

The Importance of Domain-Specific Validation

Statistical metrics and model accuracy only tell part of the story. I also had clinical experts review samples of synthetic patient records for medical plausibility. They identified issues that statistical tests missed: Gretel occasionally generated patients with conflicting diagnoses (Type 1 and Type 2 diabetes simultaneously), Mostly AI created medication combinations that would never be prescribed together due to dangerous interactions, and CTGAN produced lab value combinations that were physiologically impossible. These errors didn’t significantly hurt aggregate model performance, but they would be obvious red flags to clinicians reviewing the data.

I added post-processing rules to filter out medically implausible records: mutual exclusivity constraints for contradictory diagnoses, medication interaction checks using drug databases, and physiological range validation for lab values. This filtering removed 2-4% of generated records depending on the platform, but dramatically improved the perceived quality when domain experts reviewed the data. The lesson: synthetic data generation is not fully automated. You need domain expertise to validate outputs and implement appropriate constraints. Generic statistical quality metrics are necessary but not sufficient for real-world deployment.

How Synthetic Data Generation Fits into Modern ML Workflows

Synthetic data isn’t a replacement for real data – it’s a complement that solves specific problems. In my production workflow, I use synthetic data for three purposes: privacy-safe development environments where engineers can experiment without accessing production data, data augmentation to oversample rare but important cases that are underrepresented in real data, and external sharing when collaborating with partners who can’t access our real patient data due to legal restrictions. Each use case has different quality requirements.

For development environments, I prioritize generation speed and cost over perfect accuracy. Mostly AI’s free tier works well here. Engineers need realistic data to build and test features, but 8% model performance degradation doesn’t matter in development. For data augmentation, I use Gretel to generate synthetic examples of rare patient profiles (uncommon diagnosis combinations, edge cases) that are critical for model robustness but scarce in real data. The 3.2% performance degradation is acceptable when the alternative is a model that fails catastrophically on rare inputs. For external sharing, I use CTGAN with aggressive differential privacy settings (epsilon=0.5) because privacy is paramount even if it means higher model performance degradation.

Integration with Existing Data Pipelines

All three platforms can integrate with modern data stacks, though ease of integration varies. Gretel’s native connectors for Snowflake, Databricks, and AWS S3 made it trivial to automate synthetic data generation in our data pipeline. I set up a scheduled job that pulls fresh real data monthly, generates updated synthetic datasets, and pushes them to our development environments. Total setup time: 3 hours. Mostly AI offers API access on paid plans, which I used to build a similar automation. The API is well-documented and straightforward. CTGAN required more custom engineering – I containerized the training and generation code in Docker, deployed it on Kubernetes, and built a Flask API wrapper. This took two weeks but gave us complete control over the pipeline.

One unexpected benefit of synthetic data generation: it forced us to clean and standardize our real data. All three platforms work best with consistent formatting, proper handling of missing values, and clear column types. The process of preparing data for synthesis revealed quality issues in our production data – inconsistent date formats, undocumented categorical codes, and missing value patterns that indicated upstream data collection problems. Fixing these issues improved not just synthetic data quality but our real data pipelines too. Similar to insights from evaluating different AI platforms, the integration process itself often reveals system-level improvements.

What Privacy-Preserving Synthetic Data Can’t Do

It’s important to understand the limitations. Synthetic data generation cannot create information that doesn’t exist in the original data. If your real dataset lacks examples of a particular patient subgroup, synthetic data won’t magically generate realistic examples of that subgroup. I learned this trying to generate synthetic data for pediatric patients when my original dataset was 95% adults. The synthesizers produced child patients, but their medical profiles were essentially scaled-down adult profiles – not realistic pediatric medicine. Synthetic data amplifies patterns in your training data; it doesn’t add fundamentally new patterns.

Synthetic data also struggles with complex temporal relationships. My healthcare dataset included multiple visits per patient over time. All three platforms treated each visit as an independent record, losing the longitudinal patterns that are crucial for understanding patient trajectories. Gretel offers a sequential synthesis mode that preserves temporal ordering, but it requires careful configuration and significantly longer training times. For applications requiring strong temporal modeling – disease progression, customer lifetime value, equipment failure prediction – synthetic data generation remains challenging. The technology works best for cross-sectional tabular data where rows are independent.

Regulatory Acceptance Remains Uncertain

While synthetic data offers strong privacy protections mathematically, regulatory acceptance is still evolving. I consulted with our legal team about using synthetic data for FDA submissions and clinical trial designs. The answer was complicated: synthetic data can support exploratory analyses and method development, but regulators don’t yet accept it as a substitute for real data in pivotal studies. HIPAA’s de-identification standard recognizes synthetic data as a valid de-identification method, but only if it meets the “expert determination” criteria – requiring a qualified statistician to certify privacy protection. This adds compliance costs that offset some of the benefits.

European GDPR regulations are more ambiguous about synthetic data. The consensus is that properly generated synthetic data is not personal data and therefore not subject to GDPR restrictions, but there’s no definitive legal precedent. Some data protection authorities have issued guidance suggesting synthetic data with strong differential privacy guarantees is acceptable, while others remain cautious. If you’re deploying synthetic data in regulated contexts, budget for legal review and potentially custom privacy audits. The technology is ahead of the regulatory framework, creating uncertainty that risk-averse organizations struggle with.

Conclusion: Synthetic Data Generation Is Ready for Production, With Caveats

After generating 100,000 synthetic patient records across three platforms and deploying them in production machine learning systems, I’m convinced synthetic data generation has matured into a practical tool for privacy-preserving AI development. The technology works – Gretel, Mostly AI, and CTGAN all produced synthetic data that trained models with acceptable accuracy while protecting individual privacy. The 3-8% model performance degradation is a reasonable tradeoff for eliminating privacy risks and enabling data sharing that would otherwise be impossible. However, success requires careful platform selection, domain expertise for validation, and realistic expectations about what synthetic data can and cannot do.

My recommendation: start with Mostly AI’s free tier to experiment and validate that synthetic data generation works for your use case. If results are promising and you need production-grade quality, upgrade to Gretel for the best balance of performance, privacy, and enterprise features. Consider CTGAN only if you have specialized requirements, strong ML engineering resources, and need to generate synthetic data at massive scale where the economics favor open-source. Regardless of platform, invest in domain-specific validation, implement post-processing constraints, and maintain realistic expectations. Synthetic data generation is a powerful tool in the privacy-preserving AI toolkit, but it’s not magic – it’s sophisticated statistics that requires expertise to deploy effectively.

The future of synthetic data generation looks promising. Researchers are developing more sophisticated architectures that better preserve complex relationships, regulatory frameworks are evolving to provide clearer guidance, and costs are decreasing as competition increases. I expect synthetic data to become standard practice in regulated industries over the next 3-5 years, similar to how differential privacy has become table stakes for privacy-preserving analytics. The teams that invest in building synthetic data capabilities now will have a significant competitive advantage when privacy regulations tighten further. Start experimenting today with the platforms I’ve tested, measure results rigorously, and build institutional knowledge about what works in your specific domain. The 100,000 synthetic records I generated taught me more about privacy-preserving AI than any amount of theoretical reading could have.

References

[1] Nature Machine Intelligence – Research publication covering advances in synthetic data generation methods and privacy-preserving machine learning techniques for healthcare applications.

[2] Journal of the American Medical Informatics Association – Peer-reviewed articles on electronic health records, data privacy regulations, and validation methods for synthetic healthcare datasets.

[3] MIT Technology Review – Coverage of commercial synthetic data platforms, privacy technology developments, and real-world implementations of privacy-preserving AI systems.

[4] IEEE Transactions on Knowledge and Data Engineering – Technical papers on generative adversarial networks, differential privacy mechanisms, and statistical quality metrics for synthetic data evaluation.

[5] Health Affairs – Policy analysis of HIPAA de-identification standards, regulatory frameworks for healthcare data sharing, and the legal status of synthetic data under privacy regulations.